Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sunvozertinib (DZD9008)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Dizal Pharma

Drug class:

EGFR inhibitor, HER2 inhibitor, BTK inhibitor

Related drugs:

‹

tirabrutinib (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

trastuzumab (407)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

ibrutinib (186)

zanubrutinib (55)

acalabrutinib (41)

orelabrutinib (23)

pirtobrutinib (14)

DTRMWXHS-12 (0)

tirabrutinib (0)

›

EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: A1 - Approval DZD9008 Sensitive : A1	DZD9008 Sensitive: A1 - Approval DZD9008 Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: C3 – Early Trials DZD9008 Sensitive : C3	DZD9008 Sensitive: C3 – Early Trials DZD9008 Sensitive : C3